- Previous Close
225.37 - Open
226.00 - Bid --
- Ask --
- Day's Range
204.10 - 226.96 - 52 Week Range
133.00 - 307.98 - Volume
546,188 - Avg. Volume
423,128 - Market Cap (intraday)
32.656B - Beta (5Y Monthly) 1.19
- PE Ratio (TTM)
-- - EPS (TTM)
-7.01 - Earnings Date May 28, 2025 - Jun 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 12, 2019
- 1y Target Est
--
Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical, healthcare, and bio-technology industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It also manufactures and supplies bulk drugs, active pharmaceutical ingredients (APIs), and general and highly potent APIs; specialty chemicals comprising intermediates, fine chemicals, phosphoranes, solid quaternary ammonium compounds, wittig reagents, and various pharmaceutical and cosmetic-related products; vitamin D products and its analogues; hand and body wash, sanitizers, and antiseptics; and phase transfer catalysts, soft gel capsules, disinfectant formulations, cholesterol, lanolin-related products, and liquid and lyophilized sterile injectables. The company was founded in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.
imdcal.comRecent News: DCAL.NS
View MorePerformance Overview: DCAL.NS
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DCAL.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DCAL.NS
View MoreValuation Measures
Market Cap
35.24B
Enterprise Value
56.01B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.37
Price/Book (mrq)
0.62
Enterprise Value/Revenue
2.17
Enterprise Value/EBITDA
14.59
Financial Highlights
Profitability and Income Statement
Profit Margin
-4.14%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
26.5B
Net Income Avi to Common (ttm)
-1.1B
Diluted EPS (ttm)
-7.01
Balance Sheet and Cash Flow
Total Cash (mrq)
4.16B
Total Debt/Equity (mrq)
43.70%
Levered Free Cash Flow (ttm)
--